Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05589610 | Study of EQ101 in Adult Subjects With Moderate to Severe Alopecia Areata | PHASE2 | COMPLETED | 36 | — | — | Dec 19, 2022 | Apr 30, 2024 | Apr 10, 2025 | 5 | Australia, New Zealand |
Number of participants with treatment-related adverse events as assessed by the Common Terminology Criteria for Adverse Events (CTCAE)
| Arm | Type | Description |
|---|---|---|
| EQ101 | EXPERIMENTAL | EQ101 weekly |
| Name | Type | Description |
|---|---|---|
| EQ101 | DRUG | EQ101, 2 mg/kg, once weekly dosing, for a total of 24 doses |
Key Inclusion Criteria: 1.Subjects have AA, meeting all of the following criteria: 1. Clinical diagnosis of AA with no other aetiology of hair loss ; 2. At least 35% scalp hair loss, as defined by a SALT score ≥ 35, at Screening and Baseline. Approximately 25% of subjects with 35% to \<50% scalp h...